Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who fully understand the study and are willing to sign a consent form agreeing to participate
• People aged between 18 and 80 years old, of any gender
• People who have been diagnosed with stage III or IV non-small cell lung cancer (a type of lung cancer), confirmed through a tissue or cell sample test
• People who have previously been treated with a first-line immunotherapy drug (a type of cancer treatment that helps the immune system fight cancer) — either alone or combined with chemotherapy — for at least 35 treatment cycles, or whose cancer was stable for at least 2 years, and whose cancer has since gotten worse
• People who have at least one measurable tumour that can be tracked on scans, according to standard measurement guidelines
• People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (confirm with trial site)
• People whose blood, kidney, liver, and clotting function results meet the required levels on laboratory tests (confirm with trial site for specific values)
• People who are willing and able to attend all required study visits, follow the treatment plan, and complete all study procedures
• Women who could become pregnant, and men whose partners could become pregnant, who agree to use highly effective contraception throughout the study and for 180 days after the last dose of the study drug

Who may not be able to join:

• People who have already had two or more previous systemic (whole-body) cancer treatments
• People known to have certain specific genetic changes in their cancer cells (a sensitive EGFR mutation or ALK rearrangement) that can be targeted by other specific treatments
• People who have cancer that has spread to the brain or the lining around the brain and is causing symptoms or getting worse
• People with a history of, or currently active, autoimmune disease (where the immune system attacks the body), immune system deficiency, or who need ongoing steroid or immune-suppressing medication — though a history of an underactive thyroid, or well-controlled stable type 1 diabetes, may be exceptions (confirm with trial site)
• People with certain types of lung scarring or inflammation conditions, including those who have needed steroid treatment for a lung inflammation condition in the past
• People with known active tuberculosis, HIV infection, active hepatitis B or C, or other active infections currently requiring treatment
• People who have received certain immune-stimulating treatments within 4 weeks before starting the study, or within 5 half-lives of that drug, whichever is the longer period
• People who are pregnant, breastfeeding, planning to become pregnant, or planning to father a child from the screening visit through to 180 days after the last dose of the study drug
• People who have previously had an organ or tissue transplant from another person, or who have other conditions that make immunotherapy unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.